Unten finden Sie die vollständige Liste unserer Pressemitteilungen (Seite 13 von 28):
Centessa to begin Phase 1 trial of ORX142, an OX2R agonist, in sleep-deprived adults to assess safety and alertness effects. Data expected later in 2025.
Ocugen to begin Phase 2/3 trial of OCU410ST gene therapy for Stargardt disease following FDA clearance and positive Phase 1 safety and efficacy results.
Marker teams up with Cellipont for cGMP manufacturing of MT-601, advancing trials and prep for commercialization.
Acurx’s ibezapolstat shows promising CDI treatment results in Phase 2b trial, supporting move to Phase 3.
X-Chem appoints Stephen Fair as CFO and Maureen Hart as HR SVP to support growth and strengthen its global drug discovery operations.
Biocartis appoints Ben Svarczkopf as SVP Global Marketing to boost commercial growth and expand global reach in precision oncology solutions.
Relmada names urology expert Dr. Raj Pruthi as CMO to lead NDV-01 clinical development for NMIBC following positive Phase 2 data at AUA 2025.
Capricor earns FDA Orphan Drug Designation for BMD and reports BLA progress for Deramiocel in Duchenne Muscular Dystrophy ahead of August 2025 PDUFA date.
Synfini and O2nix Bio team up to develop first-in-class cancer therapies targeting FTSJ1, a key enzyme in metastatic cancer survival.
Dr. Edgar Charles joins Climb Bio as CMO to lead clinical strategy and development in immune-mediated diseases.
Eyestem submits Phase 1 report of Eyecyte-RPE to CDSCO after showing vision gains in dry AMD patients; Phase 2 to begin post regulatory approval.
Zealand Pharma’s GLP-1/GLP-2 agonist dapiglutide shows 11.6% weight loss and good safety in 28-week Phase 1b trial.
Akari Therapeutics gains Indian patent for PH1 ADC payload, expanding global IP for its novel immuno-oncology cancer therapies.
First patient dosed in Phase 3 trial of ifinatamab deruxtecan vs docetaxel for advanced prostate cancer by Merck and Daiichi Sankyo.
AbbVie's atogepant shows superior tolerability and efficacy vs. topiramate in Phase 3 TEMPLE migraine trial.
Biogen begins global Phase 3 BRAVE trial testing omaveloxolone in children under 16 with Friedreich ataxia (FA).
Aligos appoints pharma veteran Kieron Wesson, PhD, as VP and Head of CMC to bolster drug development efforts.
Roche’s SUNMO trial shows Lunsumio + Polivy combo significantly improves outcomes in relapsed LBCL vs. R-GemOx.
Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg leads to 21% weight loss in obesity patients without diabetes.
FDA approves Dupixent for adults with bullous pemphigoid, providing relief from blisters, itch, and steroid use.
The European Commission approved argenx's Vyvgart (efgartigimod alfa) in [INDICATION]. What the decision covers and what it means for FcRn blockers in Europe.
Aptose gets $8.5M loan from Hanmi to advance tuspetinib in AML triplet therapy. Early trial data show strong safety, remissions, and MRD negativity.
Biocon’s Varma Bhupatiraju discusses vaccine approvals, regulatory strategy, and India’s role in shaping global pharma compliance and innovation.
CagriSema shows 22.7% weight loss over 68 weeks in the REDEFINE 1 trial; results published in NEJM and presented at the American Diabetes Association.
Novo Nordisk’s Mim8 shows safe transition from emicizumab in haemophilia A patients, with high patient preference and no washout or loading dose needed.
Chugai’s NXT007 showed no bleeds and strong safety in high-dose cohorts of the Phase I/II NXTAGE study in severe hemophilia A patients.
RAPT Therapeutics appoints Drs. Braunstein and Dombkowski to its board, boosting leadership as RPT904 advances in allergy and immunology trials.
Carisma and OrthoCellix merge to form a new company focused on advancing NeoCart®, a regenerative therapy for knee cartilage repair.
Dr. Andreas Moraitis joins MBX Biosciences as SVP of Clinical Development to lead strategy for endocrine and metabolic disorder therapies.
Anne Marie Cook joins Phathom as Chief Legal Officer to lead legal and governance strategy, bringing deep pharma legal and compliance expertise.
Vertex inks exclusive deal with Ono to co-develop and commercialize povetacicept in Japan and South Korea for IgAN and pMN.
Medicus Pharma Ltd. names Andrew Smith as Chief Operating Officer, bringing over 30 years of leadership in asset management and financial operations.
FDA grants accelerated approval to Datroway for EGFR-mutated NSCLC after prior targeted and platinum chemotherapy.
CytoDyn doses first patient in Phase II trial of leronlimab for relapsed colorectal cancer, marking a key step in its oncology program.
Lexeo Therapeutics partners with PXV and venBio to launch a non-viral RNA cardiac therapy venture, backed by $40M and targeting genetic heart conditions.
Revuforj earns FDA Priority Review for treating relapsed/refractory AML with mNPM1 mutation; PDUFA date set for October 25, 2025.
Merck’s WINREVAIR shows significant benefit in newly diagnosed PAH patients in Phase 3 HYPERION trial, reducing clinical worsening risk.
Novartis completes Regulus buyout, adding RNA therapy farabursen for ADPKD to its pipeline in a major nephrology and biotech expansion move.
Nicola Heffron joins Essential Pharma as Non-Executive Director, bringing 25+ years of rare disease and oncology expertise to strengthen board leadership.
Discover Dr. Mithilesh Trivedi’s inspiring journey through pharma leadership, humility, and spiritual wisdom in Pharma Now's powerful podcast.
Amicus secures Japan approval for Pombiliti + Opfolda to treat late-onset Pompe disease, expanding access to its enzyme-enhancing therapy in major markets.
Arbor Biotechnologies appoints Pfizer veteran Dr. Mikael Dolsten to its Board, boosting strategic leadership in gene editing and biotech innovation.
Amneal reports ADL-018 matches XOLAIR® in clinical trial for CSU; FDA filing expected Q4 2025, U.S. rights secured.
Scott Madel joins Biomerica as CCO to lead global growth of inFoods® IBS, drive payer strategy, and expand commercial reach in gastroenterology diagnostics.
argenx to begin registrational trial of ARGX-119 for CMS after Phase 1b shows safety, tolerability, and improved patient outcomes.
Addex invests CHF 2M in Stalicla to advance precision therapies for autism and CNS disorders; CEO Tim Dyer joins Board ahead of Phase 2 trials.
Hans Clevers and Barbara Schädler to retire from Roche, stepping down from pRED and Group Communications roles.
Circio and NeoRegen enter preclinical stage with circVec-NICT platform to enhance delivery of RNA therapeutics.
Biogen launches global Phase 3 PROMINENT trial of felzartamab in PMN to evaluate remission outcomes vs. tacrolimus.
Protagonist PN-477, a triple agonist peptide for obesity, with oral and injectable forms set for trials in 2026.
AbbVie to buy Capstan Therapeutics for $2.1B, securing in vivo tLNP CAR-T candidate CPTX2309 and RNA delivery tech for autoimmune disease therapy.
FDA approves Takeda’s GAMMAGARD LIQUID ERC, a 10% ready-to-use IG therapy with low IgA, for PI; U.S. launch in 2026, EU in 2027 as DEQSIGA.
Rocket Pharmaceuticals receives FDA IND clearance to begin Phase 1 trial of RP-A701 for BAG3-associated dilated cardiomyopathy.
FDA accepts Allergan’s sPMA for SKINVIVE by JUVÉDERM® to treat neck lines, aiming to expand its approved use beyond cheek smoothness in U.S. adults.
T-knife Therapeutics appoints Christoph Broja, Partner at EQT Life Sciences, to its Board of Directors, strengthening its leadership in TCR-T cancer therapies.
Outlook Therapeutics appoints biopharma veteran Bob Jahr as CEO to drive growth as it advances its retinal disease treatment pipeline
Jade Biosciences names Brad Dahms CFO to support growth, advance autoimmune pipeline, and build long-term stakeholder value.
GRI Bio finalizes patient enrollment for Phase 2a trial of GRI-0621 in IPF; topline data expected Q3 2025.
Sandoz invests $440M in a new Slovenia facility to boost biosimilars production, expand EU operations, and strengthen global distribution.
Alvotech and Advanz Pharma enter supply deal for AVT10, a Cimzia® biosimilar, with European launch expected in Q4 2025.
Vertex’s ALYFTREK® approved in the EU for CF patients aged 6+ with non-class I CFTR mutations; early access in Ireland, Denmark, and Germany.
Florida’s new law enables investigational stem cell therapies; Celularity is ready with FDA-registered inventory.
Jazz secures EC nod for Ziihera, the first HER2-targeted therapy conditionally approved in the EU for advanced BTC.
PharmaTech Expo 2025, with new Contract Manufacturing & Raw Material expos, will host 400+ exhibitors and 22,000+ visitors in Gandhinagar, August 5–7.
BioVersys partners with Shionogi in a global deal to advance BV500, a broad-spectrum NTM therapy, with potential milestones up to CHF 479M.
Pelthos Therapeutics completes merger with Channel Therapeutics, raises $50.1M, and begins trading on NYSE American as "PTHS" on July 2, 2025.
Instil Bio secures FDA IND clearance to begin Phase 1 trial of AXN-2510, a PD-L1xVEGF bispecific antibody, in relapsed/refractory solid tumors.
Regeneron’s Lynozyfic wins FDA approval for relapsed/refractory multiple myeloma after ≥4 prior therapies, with strong response data from LINKER-MM1 trial.
Theratechnologies to be acquired by Future Pak affiliate for $3.01/share + CVRs worth up to $1.19; total deal could reach $254M.
FDA grants priority review to Merck's sBLA for WINREVAIR in PAH, based on Phase 3 ZENITH trial showing 76% reduction in mortality and morbidity risk.
FDA approves Hikma’s TYZAVAN™, a room-temp, ready-to-infuse vancomycin for fast treatment of sepsis and other serious infections.
Nxera earns $4.8M in milestones from Centessa after IND clearance and Phase 1 trial start for OX2R agonist ORX142 targeting neurological conditions.
Thermal Energy wins $4.1M more for a pharma heat recovery project, now worth $5.6M, aiming to cut 2,038 metric tons of CO₂ annually.
Novartis reports Phase III GCAptAIN study results for Cosentyx® in giant cell arteritis; primary endpoint not met, but safety remains consistent.
MDxHealth appoints Michael Holder as Audit Chair and announces CFO Ron Kalfus to step down; Scott McMahan named interim CFO.
Essential Pharma names Simon Ramsden as CFO and Rob Smith as CTO to boost leadership and support growth in niche pharma markets.
Explore FDC Limited's award-winning training approach with Rajesh Bhattacharjee as he shares the PAC model, TNA methods, and pharma L&D insights.
AB Science to launch Phase 3 trial of masitinib for late-stage prostate cancer, with FDA and EMA approvals and biomarker-driven patient selection.
Immuthera adds top global experts to its new advisory board to advance Treg therapies for diabetes and autoimmune diseases.
Chugai and Gero enter $250M partnership to develop novel antibody therapies for age-related diseases using Gero’s AI target discovery platform.
Conduit Pharmaceuticals files 4 new patents for AZD1656 and AZD5658, leveraging AI with Sarborg to drive IP-rich asset development in autoimmune therapies.
Baxter appoints Andrew Hider as CEO, effective Sept 2025. Hider brings life sciences automation success from ATS to drive Baxter’s next chapter.
ImmunityBio gains UK approval for ANKTIVA in bladder cancer, marking its first international market nod after strong long-term response data.
SELLAS appoints Dr. Linghua Wang to its Scientific Advisory Board, enhancing expertise in cancer genomics, AI-driven research, and precision oncology.
Clearsynth Labs secures DST-TDB funding to establish India’s first large-scale deuterated chemical facility, promoting Make in India and self-reliance.
Coartem Baby wins Swissmedic nod as first malaria treatment for infants under 4.5kg, aiming to close a deadly care gap in Africa.
Join 60+ global experts in San Francisco for the first-ever West Coast edition of the Operationalize: Expanded Access Programs Summit.
Agios adds biotech veteran Dr. Jay Backstrom to Board of Directors to strengthen clinical and regulatory strategy.
Plus Therapeutics starts dosing patients in REYOBIQ™ LM trial to optimize radiotherapy for CNS cancer metastases.
Novo Nordisk files for EMA approval of 7.2 mg Wegovy®, citing 21% average weight loss in obesity trials.
Romaco Innojet unveils a heat recovery system for fluid bed processors, reducing energy consumption by up to 60% using a smart heat pump design.
Alvotech appoints Linda Jónsdóttir as CFO to lead global financial strategy, bringing vast experience in finance, healthcare, and corporate leadership.
Ascentage’s Lisaftoclax gets China NMPA nod as first Bcl-2 inhibitor approved for CLL/SLL, offering a novel at-home oral option for relapsed patients.
Pelthos launches ZELSUVMI™, the first FDA-approved at-home gel for treating molluscum contagiosum in adults and children aged 1 year and older.
Merck to acquire Verona Pharma for $10B, gaining Ohtuvayre®, the first novel inhaled COPD therapy in 20+ years, expanding its respiratory portfolio.
Aurigene fast-tracks bispecific antibody from development to patient dosing in under a year, showcasing advanced biologics capabilities.
AVP at Cadila, Mahesh Saini shares insights on FDA remediation, QA vs QC, and building world-class pharma plants in this inspiring video interview.
Drug Safety Symposium 2025: India’s PV Evolution
Oryzon wins patent approvals in Canada and Israel for vafidemstat to treat aggression and social withdrawal in CNS disorders.
Disc Medicine appoints Nadim Ahmed, CEO of Cullinan Therapeutics, to its Board of Directors.
Vertex’s non-opioid pain treatment JOURNAVX™ honored by Premier, Inc. as a 2025 Breakthrough Innovation.
Recludix Pharma expands leadership; Dr. Brian Hodous named CSO, joined by Dr. Vic Kadambi and Kristin Polsenski in elevated roles.
BiomX starts Phase 2b trial of BX004 in cystic fibrosis; first patient dosed to assess treatment for chronic P. aeruginosa lung infections.
Katalyze AI launches Digityze on Snowflake to automate pharma document processing and accelerate biomanufacturing insights.
Aegle appoints Dr. Scott Braunstein as Chairman to guide AGLE-102’s development for rare skin disease RDEB and lead strategic growth.
Iovance appoints Corleen Roche as CFO, bringing 30+ years of biotech financial leadership to support growth and TIL therapy advancement.
Dr. Yair Lotan joins Relmada as Chair of Clinical Advisory Board to guide Phase 3 development of NDV-01 for bladder cancer.
ENTOD and VESCOP sign MoU to bridge pharma academia-industry gap, promoting R&D in pharmaceuticals, nutraceuticals, and student-led innovation.
FDA approves Biocon’s Kirsty™ as first interchangeable NovoLog® biosimilar, expanding U.S. diabetes care options.
Mukul Mehta to become CFO of Novartis in March 2026, succeeding Harry Kirsch, who retires after 22 years of service and over a decade as CFO.
Madrigal secures USPTO allowance for Rezdiffra patent, covering weight-based dosing and extending U.S. IP protection through September 2044.
Onconetix to acquire Ocuvex in a merger deal; Ocuvex holders to own 90% of the combined firm. Merger aims to advance late-stage ophthalmic treatments.
Cue Biopharma’s CUE-101 + pembrolizumab combo shows 50% ORR, 2 complete responses, and 32-month mOS in HPV+ head and neck cancer Phase 1 trial.
Anselamimab didn’t meet its primary Phase III endpoint in AL amyloidosis but showed strong benefit in a key subgroup.
Voyager unveils new gene therapy to reduce Alzheimer’s risk by lowering APOE4 and delivering protective APOE2 via TRACER capsid.
Oragenics collaborates with Sterling Pharma Solutions for GMP production of ONP-002, aiming to advance clinical trials for concussion treatment.
INBS and SMARTOX expand partnership globally, launching SmarTest Patch for continuous, non-invasive drug detection.
Rocket’s RP-A601 gets RMAT status from FDA for PKP2-ACM after promising Phase 1 results in heart function, protein expression & patient quality of life.
NKGen and HekaBio team up to accelerate approval and rollout of NK cell therapy troculeucel for neurodegenerative diseases in Japan.
Vor Bio names Dr. Qing Zuraw as Chief Development Officer, adding 25+ years of global clinical leadership to its autoimmune drug development efforts.
Winlevi Singapore Malaysia launch: Hyphens introduces Winlevi (clascoterone) in both markets, the commercial and regulatory context for Southeast Asia.
Ryan Richardson to leave BioNTech’s Management Board by Sept 2025 as part of a planned transition, marking the end of his strategic leadership since 2018.
Moleculin names Roche veteran Adriano Treve as Strategic Advisor to drive partnerships as Phase 3 AML trial advances toward key 2025–26 milestones.
This interview explores how pharma L&D is transforming into a strategic lever—integrating tech, data, and agility to boost sales outcomes and business goals.
Roche’s astegolimab shows significant benefit in Phase IIb ALIENTO COPD trial but falls short of statistical significance in Phase III ARNASA.
Sun Pharma’s ILUMYA shows significant efficacy in PsA Phase 3 trials; safety aligns with prior psoriasis data.
NKGen gains FDA Expanded Access approval for troculeucel in treating up to 20 patients with neurodegenerative diseases lacking effective therapies.
Tonix launches the “Move Fibro Forward” campaign to raise awareness and highlight unmet needs in fibromyalgia care after 15 years without new treatments.
Globus Medical appoints Keith Pfeil as CEO, sees 18.4% Q2 revenue growth; Nevro acquisition boosts sales, base business also rises.
Join global leaders in Boston on July 30–31 for the 5th Next Gen Gene Therapy Vectors Summit—exploring breakthroughs in viral and non-viral vector desig
Monte Rosa starts Phase 1 study of NEK7-targeting MRT-8102 to treat inflammation via NLRP3, IL-1β, and IL-6 modulation.
Takeda gets FDA 510(k) clearance for HyHub and HyHub Duo devices, simplifying HYQVIA infusion for PI and CIDP patients with needle-free vial transfer.
Autonomix Medical secures U.S. patent for smart torquer, boosting precision in minimally invasive, nerve-targeted treatments for high-need conditions.
AstraZeneca plans $50B U.S. investment to expand R&D and drug manufacturing, create jobs, and boost supply chain for next-gen therapies by 2030.
Biogen invests $2B to expand its North Carolina RTP facility, boosting advanced manufacturing to support its pipeline and global medicine supply.
Connect Biopharma expands its board, appoints biotech veteran Jim Schoeneck to accelerate development and commercialization of rademikibart.
Spruce Biosciences and HMNC Brain Health begin Phase 2 TAMARIND trial of tildacerfont for MDD, targeting stress-related depression using precision medicine.
DBV Technologies appoints James Briggs as Chief HR Officer to lead talent strategy and support the company's shift toward potential commercialization.
BioVie appoints Dr. Amy Chappell and Kameel Farag to its Board, strengthening leadership as it advances therapies for Parkinson’s, long COVID, and Alzheimer’s.
aTyr Pharma completes Phase 3 EFZO-FIT™ trial for efzofitimod in pulmonary sarcoidosis. Topline results expected in Q3 2025 to guide next steps.
Quanta names Vanessa Jacoby as CFO & CBO and begins dose expansion in Phase 1 trial of KRAS inhibitor QTX3034 for G12D-mutant solid tumors.
Rocket Pharma restructures to focus on AAV cardiovascular therapies, reducing workforce by 30% and delaying other programs.
Gefurulimab shows strong Phase III results in AChR+ gMG, improving MG-ADL scores with a favorable safety profile. Data to be shared with regulators.
Sanofi’s Sarclisa approved in EU with VRd for adults with newly diagnosed multiple myeloma eligible for stem cell transplant, showing deep, lasting response.
BioCardia requests PMDA consultation to review clinical data and discuss approval path for CardiAMP cell therapy for ischemic heart failure in Japan.
ICT Mumbai and ITRI sign an EOI for the ₹30 crore Mumbai Biocluster, a cutting-edge facility driving translational biopharma research, honoring Prof. M. M. Sharma.
Torrent Pharma expands its Shelcal® brand with Shelcal® Total—an adult nutrition supplement targeting bone, joint, muscle, and overall health.
FDA accepts sBLA and grants Priority Review to AstraZeneca’s Imfinzi for early gastric and GEJ cancers, with decision expected by Q4 2025.
GSK enters $500M deal with Hengrui Pharma to co-develop up to 12 drugs, boosting COPD and oncology pipelines for post-2031 growth.
Roche unveils new Alzheimer’s trial data and launches a Phase III study for early diagnosis and treatment using trontinemab and blood-based biomarkers.
Aclaris names Dr. Roland Kolbeck CSO, succeeding Dr. Joe Monahan amid retirement. Kolbeck brings 30+ years' expertise in immunology and drug development.
Tevogen unveils Tevogen.AI to enhance immunotherapy R&D using AI, in partnership with Microsoft and Databricks; aims to cut costs and speed development.
Apellis gets FDA approval for EMPAVELI to treat C3G & IC-MPGN, cutting proteinuria and helping kidney function in patients aged 12 and older.
SKYTROFA by Ascendis Pharma gains FDA approval for adult GHD, expanding its use beyond pediatric patients with weekly dosing convenience.
Bio-Rad appoints Rajat Mehta EVP of Global Commercial Operations, bringing deep diagnostics leadership experience.
Entera Bio gets FDA nod to use BMD as primary endpoint in Phase 3 EB613 trial for postmenopausal osteoporosis.
BMS and Bain Capital form NewCo with $300M to advance five immunology assets, targeting autoimmune diseases with unmet needs.
Novo Nordisk names Mike Doustdar as new CEO, effective August 7, following strong growth in International Ops.
Sanofi earns FDA orphan drug status for SAR446523, a GPRC5D-targeting antibody, aimed at treating relapsed or hard-to-treat multiple myeloma.
Altanine names Charles J. Andres, Ph.D., J.D., as CEO to lead clinical growth and innovation in drug delivery technologies across key therapeutic areas.
Asia’s top biopharma event returns to Seoul, Oct 15–17. Explore innovation, partnering, and global insights. Early-bird tickets available now!
Positive DSMB reviews allow Tenaya to advance TN-201 and TN-401 gene therapy trials for HCM and ARVC; updated results expected later in 2025.
Madrigal inks $2B licensing deal with CSPC for oral GLP-1 candidate SYH2086, aiming to start trials in 2026.
Neuronetics' study finds 70% of teens and young adults with depression improved using NeuroStar TMS, reinforcing its role as a non-drug option.
Intelligent Bio Solutions to deploy drug testing tech across the major London transport network, boosting safety at 14 sites.
RINVOQ (upadacitinib) hits primary and secondary endpoints in pivotal Phase 3 study for alopecia areata, showing major improvements in hair regrowth.
PharmaTech Expo 2025, held from August 5–7 at Helipad Exhibition Centre, Gandhinagar, showcased 400+ exhibitors and attracted over 22,000 professionals.
Plus Therapeutics to launch CNSide CSF assay in Texas this August, aiding early diagnosis of CNS metastases in cancer patients.
Charles River & BioTech Social may partner to offer CGT incubator participants up to $5M crowdfunding access via BioTech Funding Portal.
Oragenics selects Southern Star Research as CRO for Phase IIa mTBI trial of ONP-002, leveraging Australia's clinical and regulatory advantages.
Altasciences partners with VoxCell BioInnovation to integrate 3D bioprinted tissues in preclinical research, enhancing speed and human relevance.
Xencor appoints Dr. Raymond Deshaies to its board, adding decades of expertise in protein science and biopharma R&D to guide its antibody development programs.
Repligen teams up with Novasign to integrate machine learning into bioprocessing, enhance TFF systems, and advance digital twins for smarter manufacturing.
CoRegen names Dr. Sonal Gupta as CMO to lead clinical strategy and advance its SRC-3 cancer platform into the clinic, boosting biotech leadership
Certara appoints Dr. Chris Bouton as CTO to drive AI-powered biosimulation and boost model-informed drug development with a next-gen platform
GRI Bio reports early Phase 2a data for GRI-0621 in IPF, showing reduced fibrogenesis markers and no safety issues. Full results expected in Q3 2025.
Charlie Gayer to become BioCryst CEO on Jan 1, 2026, succeeding Jon Stonehouse after his Dec 2025 retirement. Gayer also joins the board with the new role.
Insights from Dr. Shuvankar Ballav on biosimilars, AI in compliance, and leadership in global regulatory affairs at IPCA.
Saudi Arabia becomes the first to approve PYRUKYND for alpha- and beta-thalassemia, expanding treatment access for adult patients.
MetaVia teams up with Syntekabio to optimize DA-1241, a GPR119 agonist showing promise in MASH and T2D, using AI-driven drug discovery tools.
Vor Bio names Dallan Murray Chief Commercial Officer. He brings 25+ years in biotech leadership, including Sarepta, Gilead, Biogen & Vertex.
Praxis’s vormatrigine shows strong efficacy and safety in Phase 2 study for adult focal onset seizures, signaling best-in-class potential.
New peer-reviewed case study highlights CannEpil®'s success in treating Lennox-Gastaut Syndrome, improving seizure control and quality of life.
Catalyst Pharmaceuticals names Dr. Daniel Curran to its Board to strengthen strategy, growth, and rare disease innovation.
FDA accepts sBLA for Breyanzi in relapsed/refractory MZL with Priority Review; decision expected by Dec 5, 2025, expanding CAR T options.
Systemair to exhibit hygiene AHUs and HVAC innovations at PharmaTech Expo 2025, Stall B-110, Hall 10, Gandhinagar, August 5–7.
Sanofi finalizes acquisition of Vigil Neuroscience to advance Alzheimer’s drug VG-3927 and expand neuro R&D.
Nxera Pharma unveils next-gen obesity pipeline with novel GPCR-targeted programs, including oral GLP-1.
Quantum BioPharma’s Lucid-MS passes Phase 1 safety trial with no adverse effects, advancing MS neuroprotection.
Conduit becomes CDT Equity, focusing on AI-driven biotech, drug repurposing, animal health, and digital asset strategy.
Silo Pharma launches a crypto treasury strategy with BTC, ETH, SOL, appoints Corwin Yu to lead and adds AI market tech.
Fortrea names Tracy Krumme as SVP of Investor Relations, bringing 30+ years of experience in CRO and healthcare to lead global IR strategy.
Clearmind gets IRB nod to start Phase 1/2a trial of CMND-100 for Alcohol Use Disorder at Hadassah Medical Center, expanding its global clinical program.
Mukesh Patale of Dr. Reddy’s shares his journey, bioprocessing insights, and leadership lessons in an inspiring Pharma Now podcast.
Sandoz partners with Elawan Energy on a 150 MW solar project in Spain to meet 90% of its European electricity demand and advance decarbonization goals.
Cormica appoints Dr. Kishore Hotha as GM of TPM Labs, bringing 20 years of global expertise in analytical sciences, regulatory strategy, and lab operations.
AbbVie is investing $195M to expand U.S. API manufacturing at its North Chicago site, boosting production for key neuroscience, immunology, and oncology drugs.
New Phase II study shows EscharEx strongly links wound bed preparation to closure in venous leg ulcers, highlighting improved healing outcomes.
Eric Risser named MacroGenics CEO and President, strengthening leadership to advance innovative antibody-based cancer therapies and strategic growth.
Onco360 partners with Regeneron to provide Lynozyfic™ for relapsed/refractory multiple myeloma, ensuring patient access & safe distribution through the REMS program.